Clinical Trial Search

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: One Year Survival Rate — 0.502 proportion of patients

Primary: Surgical Exploration — 4; 6; 9 Participants

Primary: Study Drug-related Adverse Events — 3; 6; 3; 5 Participants

Primary: To Determine the Dose Limiting Toxicities — 27 participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants

Primary: The Maximum Tolerated Dose (MTD) of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients Who Have Not Developed Distant…

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Complete Response Rate — 2; 15; 4; 3 Participants

Primary: Response Rate — .125 proportion of participants

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.

Primary: Disease Control Rate (DCR) — 73 Percentage of participants

Primary: Progression-free Survival (PFS) — 6.5; 8.4 months

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: One-year Overall Survival Rate — 46 Participants

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Overall Survival — 17.25; 17.94 months — p=0.5487

Primary: 12- Month Overall Survival (OS) — 16 Participants

Primary: Frequency of R0 Resection — 11; 2 Participants

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Progression-free Survival at 6 Months — 82 percentage of participants

Primary: (Part A Experimental Dose Level 0 Only) Safety of the Combination of BMS-813160 Plus Nivolumab Plus Gemcitabine Plus Nab-paclitaxel as Measured by Frequency, Type, and…

Primary: Progression Free Survival — 54; 97 percentage of participants